Abstract
Molecular pathology is an integral part of daily diagnostic pathology and used for classification of tumors, for prediction of prognosis and response to therapy, and to support treatment decisions. For these reasons, analyses in molecular pathology must be highly reliable and hence external quality assessment (EQA) programs are called for. Several EQA programs exist to which laboratories can subscribe, but they vary in scope, number of subscribers, and execution. The guideline presented in this paper has been developed with the purpose to harmonize EQA in molecular pathology. It presents recommendations on how an EQA program should be organized, provides criteria for a reference laboratory, proposes requirements for EQA test samples, and defines the number of samples needed for an EQA program. Furthermore, a system for scoring of the results is proposed as well as measures to be taken for poorly performing laboratories. Proposals are made regarding the content requirements of an EQA report and how its results should be communicated. Finally, the need for an EQA database and a participant manual are elaborated. It is the intention of this guideline to improve EQA for molecular pathology in order to provide more reliable molecular analyses as well as optimal information regarding patient selection for treatment.
Similar content being viewed by others
References
Dancey JE, Bedard PL, Onetto N, Hudson TJ (2012) The genetic basis for cancer treatment decisions. Cell 148:409–420
Pao W, Chmielecki J (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10:760–774
Penzel R et al (2011) EGFR mutation detection in NSCLC—assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC. Virchows Arch 458:95–98
Dequeker E, Ligtenberg MJL, Vander Borght S, Van Krieken JJM (2011) Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme. Virchows Arch 459:155–160
Bellon E et al (2011) External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. Oncologist 16:467–478
Wong NACS, Deans ZC, Ramsden SC (2012) The UK NEQAS for molecular genetics scheme for gastrointestinal stromal tumour: findings and recommendations following four rounds of circulation. J ClinPathol. doi:10.1136/jclinpath-2012-200851
International Organization for Standardization. ISO 17043:2010 Conformity assessment—general requirements for proficiency testing. http://www.iso.org/iso/catalogue_detail.htm?csnumber=29366. Accessed 28 sept 2012
Thunnissen FB et al (2004) Dutch Pathology Molecular Diagnostic Working Group. Quality control in diagnostic molecular pathology in the Netherlands; proficiency testing for patient identification in tissue samples. J Clin Pathol 57:717–720
von Wasielewski R, Krusche CA, Rüschoff J, Fisseler-Eckhoff A, Kreipe H (2008) Implementation of external quality assurance trials for immunohistochemically determined breast cancer biomarkers in Germany. Breast Care 3:128–133
International Organization for Standardization. ISO 15189:2003 Medical laboratories—particular requirements for quality and competence. http://www.iso.org/iso/catalogue_detail?csnumber=42641. Accessed 28 Sept 2012
Rudiger T, Hofler H, Kreipe HH, Nizze H, Pfeifer U, Stein H, Dallenbach FE, Fischer HP, Mengel M, von Wasielewski R, Muller-Hermelink HK (2002) Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol 26:873–882
Mengel M, von Wasielewski R, Wiese B, Rüdiger T, Müller-Hermelink HK, Kreipe H (2002) Interlaboratory and interobserver reproducibility of immunohistochemical assessment of the Ki67-labelling index in a large multi-centre trial. J Pathol 198:292–299
Thunnissen E, Bovée JV, Bruinsma H, van den Brule AJ, Dinjens W, Heideman DA, Meulemans E, Nederlof P, van Noesel C, Prinsen CR, Scheidel K, van de Ven PM, de Weger R, Schuuring E, Ligtenberg M (2011) EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy. J Clin Pathol 64:884–892
Andrew G, Carlin JB, Stern HS, Rubin DB (2003) Bayesian data analysis. Chapman & Hall, Boca Raton
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
van Krieken, J.H., Normanno, N., Blackhall, F. et al. Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Arch 462, 27–37 (2013). https://doi.org/10.1007/s00428-012-1354-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-012-1354-4